Inhibikase Therapeutics, Inc. (IKT)
1.59
-0.04
(-2.45%)
USD |
NASDAQ |
Oct 23, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
Inhibikase Therapeutics Net Income (Quarterly) : -19.59M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.59M |
| March 31, 2026 | -16.38M |
| December 31, 2025 | -12.73M |
| September 30, 2025 | -11.93M |
| June 30, 2025 | -9.916M |
| March 31, 2025 | -13.68M |
| December 31, 2024 | -12.13M |
| September 30, 2024 | -5.778M |
| June 30, 2024 | -4.960M |
| March 31, 2024 | -4.650M |
| December 31, 2023 | -4.178M |
| September 30, 2023 | -4.595M |
| June 30, 2023 | -5.778M |
| March 31, 2023 | -4.478M |
| December 31, 2022 | -4.279M |
| September 30, 2022 | -4.495M |
| June 30, 2022 | -4.640M |
| Date | Value |
|---|---|
| March 31, 2022 | -4.641M |
| December 31, 2021 | -5.042M |
| September 30, 2021 | -4.471M |
| June 30, 2021 | -2.636M |
| March 31, 2021 | -2.637M |
| December 31, 2020 | -1.208M |
| September 30, 2020 | -0.6706M |
| June 30, 2020 | -0.4219M |
| March 31, 2020 | -0.5474M |
| December 31, 2019 | -0.43M |
| September 30, 2019 | -1.212M |
| June 30, 2019 | -2.344M |
| March 31, 2019 | -1.736M |
| December 31, 2018 | -1.265M |
| March 31, 2018 | -0.125M |
| December 31, 2017 | 0.0446M |
| March 31, 2017 | -0.1856M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 19.59M |
| EPS Diluted (Quarterly) | -0.1122 |
| Enterprise Value | 50.91M |
| Earnings Yield | -27.45% |
| Normalized Earnings Yield | -27.57 |